Summary & Overview
CPT 81178: ATXN1 (ataxin 1) Repeat Expansion Detection, Technical Component
CPT code 81178 denotes a laboratory technical procedure to detect expanded sequence alleles in the ATXN1 gene (ataxin 1). This targeted molecular diagnostic test identifies pathogenic repeat expansions that are clinically relevant for conditions associated with ATXN1. Nationally, accurate coding and recognition of this test are important for appropriate laboratory billing, clinical genetics workflows, and payer coverage determinations for genetic testing.
Key payers addressed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise explanation of the clinical purpose of the test, typical sites of service, and which payers are commonly involved in coverage and reimbursement decisions. The publication outlines benchmarks related to utilization and billing practices, summarizes relevant policy considerations that affect coverage of molecular diagnostic testing, and places the test in clinical context for neurology and genetic counseling use cases.
The report also highlights common billing modifiers and operational notes where data is available, and it identifies areas where input data were not provided. The intended audience includes coding professionals, laboratory managers, genetic counselors, and payer policy analysts seeking a practical national overview of CPT code 81178 and its role in genetic diagnostic services.
Billing Code Overview
CPT code 81178 describes a molecular diagnostic laboratory test in which a laboratory analyst performs the technical procedures to detect the presence of changes in the gene ataxin 1 (ATXN1), specifically to identify abnormal alleles involving expanded sequences. This service is a genetic/diagnostic laboratory test used for detecting pathogenic repeat expansions in ATXN1.
Service type: Genetic molecular diagnostic testing (technical component)
Typical site of service: Clinical molecular laboratory or hospital laboratory
Clinical & Coding Specifications
Clinical Context
A 42-year-old adult presents to a neurology clinic with progressive cerebellar ataxia characterized by gait instability, dysarthria, and gradual coordination decline over several years. A family history is notable for similar late-onset neurodegenerative symptoms in a parent. The neurologist documents signs consistent with spinocerebellar ataxia and orders molecular diagnostic testing to evaluate for expanded CAG repeat alleles in the ATXN1 gene.
The clinical workflow begins with pre-test genetic counseling to explain indications, possible results, and implications for family members. A blood sample is collected in the outpatient lab and sent to a molecular diagnostics laboratory. The lab analyst performs the technical assay to detect expanded sequence changes in the ATXN1 gene using PCR-based sizing or fragment analysis, capillary electrophoresis, or other validated methods. Results are reviewed by the laboratory director and a written report detailing allele sizes, interpretation (normal, intermediate, or expanded pathogenic allele), and recommended follow-up is returned to the ordering clinician. Post-test genetic counseling is typically provided to discuss results, implications for prognosis, and familial testing options.
Typical site of service: outpatient physician office, outpatient draw station, or reference molecular diagnostics laboratory (off-site). Service type: diagnostic molecular genetic testing for detection of expanded alleles in the ATXN1 gene relevant to spinocerebellar ataxia type 1 (SCA1).
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
26 |